Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790075 · ClinicalTrials.gov registry record · Phase 4
Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children
A Phase 4 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00790075 is a Phase 4 study that has completed, run by Stony Brook University. The registered enrollment target is 24 participants.
The verdict
NCT00790075, a Phase 4 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this study is to demonstrate safety and efficacy of liquid risperidone in psychiatrically hospitalized children, ages 4-12, who would be put in seclusion or restraint, or given an intramuscular injection of diphenhydramine because of their out-of-control behavior if not medicated with risperidone. The first part of the study will: 1) develop appropriate oral doses of medication to reduce out of control or agitated behavior effectively with the fewest side effects, and 2) develop a rating system to measure the children's behavior i.e. level of improvement, sedation, and untoward effects.
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790075
The ClinicalTrials.gov registry entry for NCT00790075 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT00790075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790075 about?
NCT00790075 is a clinical study titled "Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children". The goal of this study is to demonstrate safety and efficacy of liquid risperidone in psychiatrically hospitalized children, ages 4-12, who would be put in seclusion or restraint, or given an intramuscular injection of diphenhydramine because of their out-of-control behavior if not medicated with ri...
What is the current status of trial NCT00790075?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2003-01. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00790075?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT00790075?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.